Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas

Cancer Discovery

Volumn 3, Issue 6, 2013, Pages 630-635

  Drilon, Alexander ^a   Wang, Lu ^a   Hasanovic, Adnan ^a   Suehara, Yoshiyuki ^a   Lipson, Doron ^b   Stephens, Phil ^b   Ross, Jeffrey ^b   Miller, Vincent ^b   Ginsberg, Michelle ^a   Zakowski, Maureen F ^a   Kris, Mark G ^a   Ladanyi, Marc ^a   Rizvi, Naiyer ^a  

^a LENOX HILL HOSPITAL   (United States)

^b FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; PROTEIN RET;

ADULT; AGED; ARTICLE; CANCER GROWTH; CASE REPORT; DIARRHEA; DRUG DOSE REDUCTION; DYSGEUSIA; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENOTYPE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; MASS SPECTROMETRY; METASTASIS; MUCOSA INFLAMMATION; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TOXICITY;

ADENOCARCINOMA; ANILIDES; DISEASE-FREE SURVIVAL; GENE FUSION; HUMANS; LUNG NEOPLASMS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES;

EID: 84878858856     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0035     Document Type: Article

References (26)

1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24.
2. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements defi ne a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
3. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and effi cacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83.
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identifi cation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
5. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
6. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508-15.
7. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-9.
8. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
9. Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 2003;195: 168-86.
10. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 1998;4:223-8.
11. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997;15:1263-73.
12. Ju Y S, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012;22:436-45.
13. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, et al. KIF5BRET: identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012;18:6599-608.
14. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-7.
15. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
16. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
17. Hirsch FR, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, et al. Epidermal growth factor receptor inhibition in lung cancer. J Thoracic Oncol 2013;8:373-84.
18. Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP, et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011;96:E991-5.
19. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9.
20. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30:4352-9.
21. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2013;8:45-51.
22. Venturini L, You J, Stadler M, Galien R, Lallemand V, Koken MH, et al. TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene 1999;18:1209-17.
23. Klugbauer S, Rabes HM. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 1999;18:4388-93.
24. The Cancer Genome Atlas. TCGA data portal overview [Internet]. Bethesda, MD: National Cancer Institute; 2012 [cited 2013 Jan 8]. Available from: https://tcga-data.nci.nih.gov/tcga/.
25. Rusch V, Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, et al. Prevalence, clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18:4910-8.
26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.